CML Publications June 2025
As part of our monthly news service we would like to make you aware of the CML publications of the month. From the many papers published every month Professor Timothy Hughes has selected topical, interesting papers for your perusal that also include interesting publications from low- and middle-income countries.
Clinical CML papers
Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic-phase: A prospective, observational study – SIMPLICITY
Mauro MJ et al. Leuk Lymphoma, June 2025 (epub ahead of print)
open access publication
Which is the best tyrosine kinase inhibitor for newly diagnosed chronic myelogenous leukemia? - Review
Shanmunagathan N et al. Am Soc Clin Oncol Educ Book, June 2025
open access publication
Asciminib for Philadelphia chromosome-positive leukemias
Hughes TP et al. Haematologica, June 2025 (epub ahead of print)
open access publication
Treatment-free remission in chronic myeloid leukemia: Revisiting the “W” questions
Bruzzese A et al. Eur J Haematol, June 2025 (epub ahead of print)
open access publication
SOHO state of the art updates and next questions: Combination therapy in chronic myeloid leukemia chronic-phase – Review
Costa A and Breccia M. Clin Lymphoma Myeloma Leuk, June 2025
Impact of tyrosine kinase inhibitors on thyroid function in chronic myeloid leukemia: A systematic review
Sardarova N et al. Cureus, June 2025
open access publication
Olverembatinib in chronic myeloid leukemia: Is less actually better?
Perusini MA and Kim DDH. Haematologica, June 2025 (epub ahead of print)
open access publication
Real-world evidence of treatment-free remission strategies and outcomes in chronic myeloid leukemia
Bourne G et al. Cancers(Basel), June 2025
open access publication
Innovative rapid screening for complex BCR-ABL kinase domain mutations in TKI-treated leukemia patients
Lan Y et al. Br J Cancer, June 2025 (epub ahead of print)
Ponatinib may make allogeneic hematopoietic stem cell transplantation unnecessary for CML-BC under conditions, such as the de novo cases: A case series of the novo CML-BC treated with ponatonib and no transplantation
Koyabu S et al. Leuk Lymphoma, June 2025
The efficacy and safety of asciminib treatment in patients with chronic myeloid leukemia as a second-line or beyond second-line treatment: A systematic review and meta analysis
Fan Z et al. Ther Adv Hematol, June 2025
open access publication
Treatment-free remission (TFR) in chronic-phase chronic myeloid leukemia CP-CML): Analysis of predictive factors and novel baseline scoring system to predict molecular relapse
Laganà A et al Eur J Haematol, June 2025 (epub ahead of print)
Scientific CML papers
BCR-ABL: The mastermind behind chronic myeloid leukemia – Review
Shammas T et al. Cytokine Growth Factor Rev, June 2025
open access publication
SUMOylation facilitates the stability of BCR-ABL to promote chronic myeloid leukemia progression
Zhang L et al. Oncogene, June 2025
Metabolomic profiling and bioanalysis of chronic myeloid leukemia: Identifiying biomarker for treatment response and disease monitoring
Sayin S et al. Metabolite, June 2025
open access publication
SMYD3 activates fatty acid beta-oxidation to promote self-renewal of leukemia stem cells
Zhou M et al. Cancer Res, June 2025
Genetic variants in oxidative stress-related genes and their impact on prognosis and treatment response in chronic myeloid leukemia patients
Alves R et al. Int J Mol, June 2025
open access publication
Pediatric CML papers
Rare manifestations of pediatric chronic myeloid leukemia: A case report on priapism and a literature review
Budair R et al. Front Oncol, June 2025
open access publication
Quality of life and adherence to tyrosine kinase inhibitors among pediatric, adolescent, and young adult chronic myeloid leukemia patients: A systematic Review
Werk RS et al. Pediatr Blood Cancer, June 2025
open access publication